20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
The system is equipped with the most up-to-date technology. The R&D activity, which produces continuous improvements in the performance of the technology and in the knowledge will end up optimizing the process. Now, we aim at integrating the MICROBALANCE results with anamnestic data and with the results from the other HELIXAFE tests by the development of our AI. The following step will be to receive validation of the AI’s ability to integrate the information obtained from MICROBALANCE, from the anamnesis, and from the other HELIXAFE tests, to profile an individual based on their detected colorectal cancer risks. Eventually, we will also try to combine MICROBALANCE with the analysis of other cancer drivers (mitochondrial dysfunction), to further increase the gut dysbiosis analysis’ predictive value.
